

## Cumulative indices for 2008

## Author Index

- Abdollahi M  
5(2), 215–222
- Ahmad S  
5(2), 139–144
- Ahrén B  
5(1), 79–90
- Aktas S  
5(1), 99–108
- Anderson JL  
5(2), 125–128
- Arlen PM  
5(1), 1–2
- Arya R  
ary
- Ault K  
5(3), 279–281
- Balaratnam S  
5(2), 151–157
- Bosch FX  
5(3), 305–312
- Brenner B  
5(2), 123–124
- Brotherton J  
5(3), 283–287
- Carlquist JF  
5(2), 125–128
- Castellsagué X  
5(3), 305–312
- Chen JJ  
5(2), 203–214
- Chordia P  
5(3), 367–375
- Cohen AT  
5(2), 151–157
- Culig Z  
5(1), 47–56
- Dahut W  
5(1), 57–61
- Daley P  
5(3), 367–375
- Das P  
5(2), 139–144
- Dashtipour K  
5(2), 203–214
- Davies J  
5(1), 37–45
- de Sanjosé S  
5(3), 305–312
- Del Vecchio L  
5(1), 91–98
- Denny L  
5(3), 329–338
- Dieter RS  
5(2), 139–144
- Dillner J  
5(3), 289–294
- Drummond A  
5(2), 195–197
- Eardley I  
5(3), 355–365
- Falanga A  
5(2), 145–147
- Fassiadis N  
5(2), 151–157
- Fitzmaurice DA  
5(2), 129–131
- Franco E  
5(3), 261–263
- French KM  
5(3), 289–294
- Garnett G  
5(3), 289–294
- Gravitt P  
5(3), 295–303
- Gulley JL  
5(1), 3–5
- Hardev P  
5(1), 37–45
- Harper D  
5(3), 313–324
- Harenberg J  
5(2), 177–192
- Hobisch A  
5(1), 47–56
- Hoffman R  
5(2), 149–150
- Ismail M  
5(1), 37–45
- Jellinger KA  
5(2), 237–255
- Karakunnel J  
5(1), 57–61
- Kaufmann AM  
5(3), 339–348
- Kumar S  
5(2), 223–235
- Kyprianou N  
5(1), 7–11
- Larijani B  
5(2), 215–222
- Lee RJ  
5(1), 63–72
- Legg L  
5(2), 195–197
- Lehtinen M  
5(3),
- Lew MF  
5(2), 203–214
- Lip GYH  
5(2), 139–144
- Locatelli F  
5(1), 91–98
- Lois K  
5(2), 223–235
- Malik A  
5(1), 109–117
- Mandapaka S  
5(2), 139–144
- Meyer G  
5(2), 159–167
- Monsonogo J  
5(3), 269–272
- Mouraviev P  
5(1), 25–36
- Myatt A  
5(3), 355–365
- Nanjundappa A  
5(2), 139–144
- Nishida KJ  
5(3), 265–268
- Paavonen J  
5(3), 261–263; 5(3), 289–294;  
5(3), 325–328
- Patel RK  
5(2), 169–175
- Pearson JM  
5(3), 265–268
- Planquette B  
5(2), 159–167
- Polascik TJ  
5(1), 25–36
- Pozzoni P  
5(1), 91–98
- Roden RBS  
5(3), 295–303
- Salari P  
5(2), 215–222
- Sanchez O  
5(2), 159–167
- Schneider A  
5(3), 339–348
- Skinner R  
5(3), 283–287
- Smith MR  
5(1), 63–72
- Taggar JS  
5(2), 139–144
- Trimble CL  
5(3), 295–303
- Twiggs LB  
5(3), 265–268
- Uzun G  
5(1), 99–108
- Vaidya V  
5(1), 109–117
- Yildiz S  
5(1), 99–108

## Compound Index

- Acenocoumarol  
5(2), 177–192

## APPENDICES

Cumulative indices for 2008

Adrostenedione	5(1), 47–56	Estramustine	5(1), 57–61	Prednisone	5(1), 57–61
Alfuzosin	5(3), 355–365	fluazetil	5(2), 237–255	Protamine	5(2), 177–192
Amitriptyline	5(2), 203–214	Fluoxetine	5(2), 203–214	Rasagiline	5(2), 203–214
Apixaban	5(2), 177–192	Fluramine	5(2), 223–235	Rimonabant	5(2), 223–235
Argatroban	5(2), 149–150	Fluvoxamine	5(2), 203–214	Rivaroxaban	5(2), 177–192; 5(2), 149–150
Atomoxetine	5(1), 109–117	Folate	5(2), 215–222	Ropinirole	5(2), 203–214
Atrasentan	5(1), 57–61	Fondaparinux	5(2), 149–150	Selegiline	5(2), 203–214
Avanafil	5(3), 355–365	Gardasil	5(3), 289–294; 5(3), 305–312; 5(3), 325–328; 5(3), 329–338	Sibutramine	5(2), 223–235
Bevacizumab	5(1), 57–61	Heparin	5(2), 177–192	Sildenafil	5(3), 355–365
Bicalutamide	5(1), 47–56	Hydroxyflutamide	5(1), 47–56	Sorafenib	5(1), 57–61
Bisphosphonates	5(1), 63–72	Idraparinux	5(2), 177–192	Sulphonylurea	5(1), 79–90
Bombesin	5(1), 47–56	Insulin	5(1), 79–90	Sunitinib	5(1), 57–61
Bortezomib	5(1), 57–61	Ketoconazole	5(1), 47–56	Tadalafil	5(3), 355–365
Bupropion	5(2), 203–214	Lepirudin	5(2), 149–150	Tamsulosin	5(3), 355–365
Cediranib	5(1), 57–61	Levitra®	see vardenafil	Thalidomide	5(1), 57–61
Cervarix	5(3), 305–312; 5(3), 329–338; 5(3), 289–294	Levodopa	5(2), 237–255; 5(2), 203–214	Thiazolidinedione	5(1), 79–90
Cialis™	see Tadalafil	L-threo-dops	5(2), 237–255	Topamax®	see topiramate
Citalopram	5(2), 203–214	Metformin	5(1), 79–90	Topiramate	5(1), 79–90
Clomipramine	5(2), 203–214	Methamphetamine	5(2), 237–255	Trazodone	5(2), 203–214
Darbepoetin alpha	5(1), 91–98	Mianserin	5(2), 203–214	Vardenafil	5(3), 355–365
D-fenfluramine	5(1), 109–117	Mirtazapine	5(2), 203–214	Venlafaxine	5(2), 203–214
Docetaxel	5(1), 57–61	Nefazodone	5(2), 203–214	Viagra®	see sildenafil
Doxazosin	5(3), 355–365	Nortriptyline	5(2), 203–214	Vildagliptin	5(1), 79–90
Doxepin	5(2), 203–214	Orlistat	5(2), 223–235	Vitamin D	5(1), 57–61
Enoxaparin	5(2), 149–150; 5(2), 177–192	Orskolin	5(1), 47–56	Warfarin	5(2), 125–128; 5(2), 129–131; 5(2), 177–192
Epoetin alpha	5(1), 91–98	Otamixaban	5(2), 177–192	Xinlay™	see Atrasentan
Epoetin beta	5(1), 91–98	Pamidronate	5(1), 63–72	Zoledronic acid	5(1), 63–72
Epoetin delta	5(1), 91–98	Paroxetine	5(2), 203–214	Zometa	see zoledronic acid
Escitalopram	5(2), 203–214	Pramipexole	5(2), 203–214		